| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Knight Therapeutics Inc. (TSX:GUD) (“Knight” or “the Company”) announced today that its Colombian affiliate, Biotoscana Farma S.A. has obtained INVIMA approval for Lenvima® (lenvatinib), the orally available multiple receptor tyrosine kinase inhibitor developed by Eisai, for the treatment of radioiodine refractory differentiated thyroid cancer (RR-DTC) and unresectable hepatocellular carcinoma (u-HCC).
Lenvima® (lenvatinib) demonstrated a statistically significant progression-free survival prolongation and response rate in patients with progressive, differentiated thyroid cancer who had become refractory to radioactive iodine therapy1. In a separate study in patients with previously untreated unresectable HCC2, Lenvima® (lenvatinib) was proven to be non inferior to sorafenib for overall survival. In addition, Lenvima® (lenvatinib) was statistically significantly superior to sorafenib for progression-free survival and objective response rate. In 2020, there were approximately 5,3043 new patients with thyroid cancer and 2,2893 new patients with liver cancer in Colombia.
“We’re pleased to announce the approval of Lenvima® (lenvatinib) in Colombia as it provides a new treatment option for radioiodine refractory differentiated thyroid cancer and unresectable hepatocellular carcinoma,” said Samira Sakhia, President & Chief Executive Officer. “We look forward to working with payors to ensure access to the product for all patients who can benefit from Lenvima® (lenvatinib).”
Knight has an exclusive license from Eisai to commercialize Lenvima® (lenvatinib), Halaven® (eribulin mesylate), Fycompa® (perampanel) and Inovelon® (rufinamide) throughout Latin America, with the exception of Mexico where Eisai retains the rights to Halaven® (eribulin mesylate) and Lenvima® (lenvatinib).
Posted In: TSX:GUD
